Roxana S Dronca

Roxana S Dronca

UNVERIFIED PROFILE

Are you Roxana S Dronca?   Register this Author

Register author
Roxana S Dronca

Roxana S Dronca

Publications by authors named "Roxana S Dronca"

Are you Roxana S Dronca?   Register this Author

36Publications

635Reads

37Profile Views

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.

Front Immunol 2018 27;9:1739. Epub 2018 Jul 27.

Department of Immunology, Mayo Clinic, Rochester, MN, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01739DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072836PMC
September 2019

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.

Future Oncol 2019 Aug 12;15(22):2645-2656. Epub 2019 Jul 12.

Division of Hematology & Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0183DOI Listing
August 2019

Immune Checkpoint Inhibitor Toxicities.

Mayo Clin Proc 2019 Jul;94(7):1321-1329

Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2019.03.012DOI Listing
July 2019

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.

Cancer Med 2017 Oct 6;6(10):2203-2212. Epub 2017 Sep 6.

Department of Oncology, Division of Medical Oncology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota, 55905, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633552PMC
October 2017

Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.

Melanoma Res 2017 02;27(1):32-42

aDepartment of Health Science Research, Division of Biomedical Statistics and Informatics bDepartment of Medical Oncology cDepartment of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000290DOI Listing
February 2017

A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.

SOJ Immunol 2017 25;5(1):1-5. Epub 2017 Feb 25.

Department of Immunology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884168PMC
February 2017

BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.

Immunotherapy 2016 12 27;8(12):1351-1353. Epub 2016 Oct 27.

Department of Immunology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2016-0100DOI Listing
December 2016

The use of pembrolizumab for the treatment of metastatic uveal melanoma.

Melanoma Res 2016 06;26(3):300-3

Departments of aOncology bHematology cImmunology, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000242DOI Listing
June 2016

Immunomodulatory antibody therapy of cancer: the closer, the better.

Clin Cancer Res 2015 Mar 28;21(5):944-6. Epub 2014 Oct 28.

Department of Urology, College of Medicine, Mayo Clinic, Rochester, Minnesota. Department of Immunology, College of Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-2111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348171PMC
March 2015

A gender factor in shaping T-cell immunity to melanoma.

Front Oncol 2015 2;5. Epub 2015 Feb 2.

Department of Urology, College of Medicine, Mayo Clinic , Rochester, MN , USA ; Department of Immunology, College of Medicine, Mayo Clinic , Rochester, MN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313609PMC
February 2015

Rare presentations of primary melanoma and special populations: a systematic review.

Am J Clin Oncol 2014 Dec;37(6):635-41

Departments of *Oncology †Surgery ‡Laboratory Medicine and Pathology §Ophthalmology #Dermatology ‡‡Radiation Oncology **Pediatrics §§Radiology ∥∥Hematology ¶¶Immunology ††Medical Genetics, Mayo Clinic, Rochester, MN ∥Department of Pediatric Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada ¶The Queen's Medical Center/Queen's Cancer Center, University of Hawaii/John A. Burns School of Medicine, Honolulu, HI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3182868e82DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349521PMC
December 2014

Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.

Am J Clin Oncol 2014 Aug;37(4):369-76

*Mayo Clinic Rochester, Rochester †Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN ‡Mayo Clinic Arizona, Scottsdale, AZ §Columbus CCOP, Columbus, OH ∥Montana Cancer Consortium, Billings, MT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e31827b45d4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348017PMC
August 2014

Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Mayo Clin Proc 2014 Apr;89(4):520-35

Department of Oncology, Mayo Clinic, Rochester, MN; Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2014.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286150PMC
April 2014

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

J Thorac Oncol 2013 Oct;8(10):1335-8

*Department of Oncology, Mayo Clinic, Rochester, Minnesota; †Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; ‡Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; §GlaxoSmithKline, Philadelphia, Pennsylvania; and ‖Early Drug Development Center, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a00f41DOI Listing
October 2013

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.

BJU Int 2013 Jun 2;111(7):1046-53. Epub 2013 Apr 2.

Department of Internal Medicine, Mayo Clinic and Mayo Medical School, 200 First Street SW, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.12075DOI Listing
June 2013

Personalized therapy for metastatic melanoma: could timing be everything?

Future Oncol 2012 Nov;8(11):1401-6

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012533PMC
November 2012

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma.

Leuk Res 2010 Sep 1;34(9):1235-8. Epub 2010 Apr 1.

Division of Hematopathology, Mayo Clinic, 200 1(st) Street SW, Hilton 8200, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2010.03.020DOI Listing
September 2010

VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.

Nat Clin Pract Oncol 2008 Sep 22;5(9):504-5. Epub 2008 Jul 22.

Division of Hematology, at the Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1202DOI Listing
September 2008